Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers

Clinical Nephrology

Volumn 73, Issue 5, 2010, Pages 370-373

  How, P P ^a,c   Mason, D L ^a   Arruda, J A ^b   Lau, A H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chronic kidney disease; Hyperparathyroidism; Hyperphosphatemia; Phosphate binders

Indexed keywords

LANTHANUM CARBONATE; PHOSPHORUS;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BLOOD SAMPLING; CHEWABLE TABLET; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG BINDING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ELEMENTAL DIET; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE INTAKE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINALYSIS;

EID: 77951653555     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73370     Document Type: Article

References (10)

1. Chiang SS et al. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol. 2005; 63: 461-470. (Pubitemid 40872625)
2. D'Haese PC et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 2003; 85 (Suppl): S73-S78.
3. Finn WF et al. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol. 2004; 62: 193-201.
4. Finn WF et al. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006; 65: 191-202.
5. Friedlander G. Regulation of renal phosphate handling: recent findings. Curr Opin Nephrol Hypertens. 1996; 5: 316-320. (Pubitemid 26248999)
6. Hutchison AJ et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100: c8-c19.
7. Hutchison AJ et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.Nephron Clin Pract. 2006; 102: c61-c71.
8. Joy MS et al. Randomized, double-blind, placebocontrolled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003; 42: 96-107.
9. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care. 2008; 35: 215-237. (Pubitemid 351680116)
10. Source of basic data Build Study, 1979. Society of Actuaries and Association of Life Insurance Medical Directors of America, 1980. Copyright© 1996, 1999 Metropolitan Life Insurance Company. (http://www.bcbst.com/mpmanual/HW.htm) Accessed March 2006.